An Evaluation of the Potential for VH4011499 Drug-drug-interactions
A Phase 1, Open-label Study to Evaluate the Potential for VH4011499 Drug-drug-interactions in HIV Negative Adult Participants
The purpose of this study is to evaluate the pharmacokinetic (PK) interactions between VH4011499 and representative drugs containing inhibitors and inducers, selected transporters, and statins, in HIV negative adults. The study will also assess to assess safety and tolerability during co-administration of VH4011499 with the selected drugs.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Fase 1
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: US GSK Clinical Trials Call Center
- Numero di telefono: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
Backup dei contatti dello studio
- Nome: EU GSK Clinical Trials Call Center
- Numero di telefono: +44 (0) 20 89904466
- Email: GSKClinicalSupportHD@gsk.com
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
-
Participants must be 18 to 60 years of age inclusive at the time of signing the informed consent form (ICF).
-
Male or female:
-
Male Participants:
No restrictions for male participants.
-
A female participant (female sex assigned at birth) is eligible to participate if:
-
They are a woman of non-child bearing potential (WONCBP). There is no requirement for female study participants to use a highly effective method of contraception since, to be eligible, they must be of nonchildbearing potential.
- Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, vital signs, cardiac monitoring, and clinical laboratory evaluations at Screening.
- Body weight ≥50.0 kg (110 lbs) for men and ≥45.0 kg (99 lbs) for women and body mass index within the range 18.5 to 32.0 kg/m^2 (inclusive).
- Capable of giving signed informed consent.
Exclusion Criteria:
- History or presence of clinical condition or disorder that could be capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study drugs, interfering with the interpretation of data or would make the participant unsuitable for the study; unable to comply with dosing requirements; or unable to comply with study visits.
- Pre-existing clinically relevant, gastro-intestinal pathology or diagnosis.
- A history, or current abnormality in glucose metabolism requiring concomitant use of insulin or other medications for glucose control.
- Clinically significant abnormal blood pressure at Screening.
- Lymphoma, leukemia, or any malignancy within the past 5 years (with specified exceptions) or breast cancer within the past 10 years.
- Breast cancer within the past 10 years.
- Current or chronic history of liver disease or known hepatic or biliary abnormalities, or history of hepatic porphyria.
- History of syncope, clinically significant palpitations, cardiac arrhythmias or other cardiac diseases or a family and personal history of long QT syndrome.
- History of seizure(s) and / or other clinically significant neurological conditions.
- Pre-existing psychiatric condition, that would pose a safety risk to the participant or interfere with participation in the study.
- Participants with any history of any drug hypersensitivity, delayed-type hypersensitivity, or severe hypersensitivity reactions, as well as history of sensitivity to the study interventions.
- Participant is mentally or legally incapacitated.
- Cohort 3: VH4011499 + Carbamazepine ONLY: Participants who are carriers of the HLA-B*15:02 and/or HLA-A*31:01 gene.
- Cohort 3: VH4011499 + Carbamazepine ONLY: History of bone marrow depression, aplastic anemia, agranulocytosis, or other clinically significant hematologic or bone marrow disorder.
- Unable to refrain from the use of prescription or non-prescription medications.
- Use of monoamine oxidase inhibitors (MAOIs) within 14 days prior to Day -1.
- Cohort 3:VH4011499 + Carbamazepine ONLY: Known hypersensitivity to carbamazepine, oxcarbazepine, or tricyclic compounds.
- Exposure to more than 4 new investigational products within 12 months prior to the first dosing day.
- Current enrollment or past participation in another investigational study in which an investigational intervention, within the protocol-defined exclusion period.
- Participant has donated or lost blood, or has donated plasma within 30 days prior to first administration.
- Current enrollment or past participation in this clinical study.
- Unwillingness or inability to follow the procedures outlined in the protocol.
- eGFR <90 mL/min or serum creatinine >1.1× upper limit of normal (ULN) .
- Hemoglobin <12.5 g/dL for men and <11 g/dL for women.
- Participants with active hepatitis B virus (HBV) based on any of the following are excluded: 1) Positive hepatitis B surface antigen (HBsAg), 2) Positive hepatitis B surface antibody (HBcAb) except HBV DNA is negative.
- Positive Hepatitis C antibody test result at Screening.
- Positive pre-study drug/alcohol screen.
- Positive HIV-1 antibody / antigen fourth generation test (point of care test or laboratory immunoassay) and / or acute viral symptoms with no alternative etiology within 3 weeks prior to Screening.
- Cohort 3: VH4011499 + Carbamazepine ONLY: Clinically significant hematologic abnormalities at Screening.
- Cohort 3: VH4011499 + Carbamazepine ONLY: Serum sodium <135 millimole/L.
- Regular alcohol consumption within 6 months prior to Screening.
- Regular use of known drugs of abuse.
- Urinary cotinine levels indicative of smoking or history or regular use of tobacco- or nicotine-containing products within 6 months prior to Screening and at admission.
- Sensitivity to the study drugs, or components thereof, or other drug or other allergy that, contraindicates participation in the study.
- Prior exposure to VH4011499 or Lenacapavir in any formulation..
- Study participants with ALT >1.0x ULN or total bilirubin >1.5x ULN are excluded at Screening.
- Any significant arrhythmia or ECG findings meeting protocol-defined exclusion criteria.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Scienza basilare
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Cohort 1: VH4011499 + Ritonavir
Participants receive a single dose of VH4011499 at Day 1, followed by a 21-day washout period. On days 23-54, participants receive Ritonavir twice daily. On Day 26, participants receive another single dose of VH4011499, along with Ritonavir. |
VH4011499 is administered to the participants based on the protocol schedule. Ritonavir is administered to the participants based on the protocol schedule. |
|
Sperimentale: Cohort 2: VH4011499 + Efavirenz
Participants receive a single dose of VH4011499 at Day 1, followed by a 21-day washout period. On days 23-58, participants receive Efavirenz once daily. On Day 37, participants receive another single dose of VH4011499, along with Efavirenz. |
VH4011499 is administered to the participants based on the protocol schedule. Efavirenz is administered to the participants based on the protocol schedule. |
|
Sperimentale: Cohort 3: VH4011499 + Carbamazepine
Participants receive a single dose of VH4011499 at Day 1, followed by a 21-day washout period. On days 23-25, participants receive Carbamazepine low dose; on days 26-28, they receive Carbamazepine medium dose; and on days 29-62, they receive Carbamazepine high dose. On Day 41, the participants receive another single dose of VH4011499, along with Carbamazepine high dose. |
VH4011499 is administered to the participants based on the protocol schedule. Carbamazepine is administered to the participants based on the protocol schedule. |
|
Sperimentale: Cohort 4: VH4011499 + Metformin + Digoxin
Participants receive a dose of Metformin and Digoxin on Day 1, followed by a 14-day washout period. On days 10-24, participants receive VH4011499 once daily (a higher dose on Day 10, followed by a lower dose on days 11-24). On Day 16, participants receive another dose of Metformin and Digoxin, along with VH4011499. |
VH4011499 is administered to the participants based on the protocol schedule. Metformin is administered to the participants based on the protocol schedule. Digoxin is administered to the participants based on the protocol schedule. |
|
Sperimentale: Cohort 5: VH4011499 + Rosuvastatin + Pitavastatin
Participants receive a dose of Rosuvastatin on Day 1, and a dose of Pitavastatin on Day 5, followed by a 10-day washout period. On days 11-26, participants receive VH4011499 once daily (a higher dose on Day 11, followed by a lower dose on days 12-26). On Day 17, participants receive another dose of Pitavastatin, and on Day 22 they receive another dose of Rosuvastatin, along with VH4011499. |
VH4011499 is administered to the participants based on the protocol schedule. Rosuvastatin is administered to the participants based on the protocol schedule. Pitavastatin is administered to the participants based on the protocol schedule. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Lasso di tempo |
|---|---|
|
Maximum plasma concentration (Cmax) of VH4011499 when administered alone
Lasso di tempo: Day 1 for Cohorts 1, 2 and 3
|
Day 1 for Cohorts 1, 2 and 3
|
|
Cmax of VH4011499 when co-administered with Ritonavir
Lasso di tempo: Day 26
|
Day 26
|
|
Cmax of VH4011499 when co-administered with Efavirenz
Lasso di tempo: Day 37
|
Day 37
|
|
Cmax of VH4011499 when co-administered with Carbamazepine
Lasso di tempo: Day 41
|
Day 41
|
|
Area under the concentration-time curve from 0 to tau [AUC(0-t)] of VH4011499 when administered alone
Lasso di tempo: Day 1 for Cohorts 1, 2 and 3
|
Day 1 for Cohorts 1, 2 and 3
|
|
AUC(0-t) of VH4011499 when co-administered with Ritonavir
Lasso di tempo: Day 26
|
Day 26
|
|
AUC(0-t) of VH4011499 when co-administered with Efavirenz
Lasso di tempo: Day 37
|
Day 37
|
|
AUC(0-t) of VH4011499 when co-administered with Carbamazepine
Lasso di tempo: Day 41
|
Day 41
|
|
Area under the concentration-time curve from 0 to infinity [AUC(0-inf)] of VH4011499 when administered alone
Lasso di tempo: Day 1 for Cohorts 1, 2 and 3
|
Day 1 for Cohorts 1, 2 and 3
|
|
AUC(0-inf) of VH4011499 when co-administered with Ritonavir
Lasso di tempo: Day 26
|
Day 26
|
|
AUC(0-inf) of VH4011499 when co-administered with Efavirenz
Lasso di tempo: Day 37
|
Day 37
|
|
AUC(0-inf) of VH4011499 when co-administered with Carbamazepine
Lasso di tempo: Day 41
|
Day 41
|
|
Cmax of Metformin when administered alone
Lasso di tempo: Day 1
|
Day 1
|
|
Cmax of Metformin when co-administered with VH4011499
Lasso di tempo: Day 16
|
Day 16
|
|
AUC(0-t) of Metformin when administered alone
Lasso di tempo: Day 1
|
Day 1
|
|
AUC(0-t) of Metformin when co-administered with VH4011499
Lasso di tempo: Day 16
|
Day 16
|
|
AUC(0-inf) of Metformin when administered alone
Lasso di tempo: Day 1
|
Day 1
|
|
AUC(0-inf) of Metformin when co-administered with VH4011499
Lasso di tempo: Day 16
|
Day 16
|
|
Cmax of Digoxin when administered alone
Lasso di tempo: Day 1
|
Day 1
|
|
Cmax of Digoxin when co-administered with VH4011499
Lasso di tempo: Day 16
|
Day 16
|
|
AUC(0-t) of Digoxin when administered alone
Lasso di tempo: Day 1
|
Day 1
|
|
AUC(0-t) of Digoxin when co-administered with VH4011499
Lasso di tempo: Day 16
|
Day 16
|
|
AUC(0-inf) of Digoxin when administered alone
Lasso di tempo: Day 1
|
Day 1
|
|
AUC(0-inf) of Digoxin when co-administered with VH4011499
Lasso di tempo: Day 16
|
Day 16
|
|
Cmax of Rosuvastatin when administered alone
Lasso di tempo: Day 5
|
Day 5
|
|
Cmax of Rosuvastatin when co-administered with VH4011499
Lasso di tempo: Day 22
|
Day 22
|
|
AUC(0-t) of Rosuvastatin when administered alone
Lasso di tempo: Day 5
|
Day 5
|
|
AUC(0-t) of Rosuvastatin when co-administered with VH4011499
Lasso di tempo: Day 22
|
Day 22
|
|
AUC(0-inf) of Rosuvastatin when administered alone
Lasso di tempo: Day 5
|
Day 5
|
|
AUC(0-inf) of Rosuvastatin when co-administered with VH4011499
Lasso di tempo: Day 22
|
Day 22
|
|
Cmax of Pitavastatin when administered alone
Lasso di tempo: Day 1
|
Day 1
|
|
Cmax of Pitavastatin when co-administered with VH4011499
Lasso di tempo: Day 17
|
Day 17
|
|
AUC(0-t) of Pitavastatin when administered alone
Lasso di tempo: Day 1
|
Day 1
|
|
AUC(0-t) of Pitavastatin when co-administered with VH4011499
Lasso di tempo: Day 17
|
Day 17
|
|
AUC(0-inf) of Pitavastatin when administered alone
Lasso di tempo: Day 1
|
Day 1
|
|
AUC(0-inf) of Pitavastatin when co-administered with VH4011499
Lasso di tempo: Day 17
|
Day 17
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Number of participants with adverse events (AEs), overall and by grade.
Lasso di tempo: Days 1 to 55 for VH4011499+Ritonavir Group; Days 1 to 59 for VH4011499+Efavirenz Group; Days 1 to 66 for VH4011499+Carbamazepine Group; Days 1 to 44 for VH4011499+Metformin+Digoxin Group; Days 1 to 44 for VH4011499+Rosuvastatin+Pitavastatin Group.
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. The intensity of AEs is reported based on the Division of acquired immunodeficiency syndrome (DAIDS) grading scale, where Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=potentially life-threatening, Grade 5=death. |
Days 1 to 55 for VH4011499+Ritonavir Group; Days 1 to 59 for VH4011499+Efavirenz Group; Days 1 to 66 for VH4011499+Carbamazepine Group; Days 1 to 44 for VH4011499+Metformin+Digoxin Group; Days 1 to 44 for VH4011499+Rosuvastatin+Pitavastatin Group.
|
|
Number of participants with AEs leading to study treatment discontinuation
Lasso di tempo: Days 1 to 55 for VH4011499+Ritonavir Group; Days 1 to 59 for VH4011499+Efavirenz Group; Days 1 to 66 for VH4011499+Carbamazepine Group; Days 1 to 44 for VH4011499+Metformin+Digoxin Group; Days 1 to 44 for VH4011499+Rosuvastatin+Pitavastatin Group.
|
Days 1 to 55 for VH4011499+Ritonavir Group; Days 1 to 59 for VH4011499+Efavirenz Group; Days 1 to 66 for VH4011499+Carbamazepine Group; Days 1 to 44 for VH4011499+Metformin+Digoxin Group; Days 1 to 44 for VH4011499+Rosuvastatin+Pitavastatin Group.
|
|
|
Number of participants with change from baseline in alanine transaminase (ALT), alkaline phosphatase (ALP), aspartate aminotransferase (AST), direct bilirubin and total bilirubin
Lasso di tempo: Days 1 to 55 for VH4011499+Ritonavir Group; Days 1 to 59 for VH4011499+Efavirenz Group; Days 1 to 66 for VH4011499+Carbamazepine Group; Days 1 to 44 for VH4011499+Metformin+Digoxin Group; Days 1 to 44 for VH4011499+Rosuvastatin+Pitavastatin Group.
|
Days 1 to 55 for VH4011499+Ritonavir Group; Days 1 to 59 for VH4011499+Efavirenz Group; Days 1 to 66 for VH4011499+Carbamazepine Group; Days 1 to 44 for VH4011499+Metformin+Digoxin Group; Days 1 to 44 for VH4011499+Rosuvastatin+Pitavastatin Group.
|
|
|
Number of participants with maximum toxicity grade increase in alanine transaminase (ALT), alkaline phosphatase (ALP), aspartate aminotransferase (AST), direct bilirubin and total bilirubin
Lasso di tempo: Days 1 to 55 for VH4011499+Ritonavir Group; Days 1 to 59 for VH4011499+Efavirenz Group; Days 1 to 66 for VH4011499+Carbamazepine Group; Days 1 to 44 for VH4011499+Metformin+Digoxin Group; Days 1 to 44 for VH4011499+Rosuvastatin+Pitavastatin Group.
|
The toxicity is reported based on DAIDS grading scale, where Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=potentially life-threatening, Grade 5=death. |
Days 1 to 55 for VH4011499+Ritonavir Group; Days 1 to 59 for VH4011499+Efavirenz Group; Days 1 to 66 for VH4011499+Carbamazepine Group; Days 1 to 44 for VH4011499+Metformin+Digoxin Group; Days 1 to 44 for VH4011499+Rosuvastatin+Pitavastatin Group.
|
|
Time to maximum plasma concentration (Tmax) of VH4011499 when administered alone.
Lasso di tempo: Day 1 for Cohorts 1, 2 and 3
|
Day 1 for Cohorts 1, 2 and 3
|
|
|
Tmax of VH4011499 when co-administered with Ritonavir
Lasso di tempo: Day 26
|
Day 26
|
|
|
Tmax of VH4011499 when co-administered with Efavirenz
Lasso di tempo: Day 37
|
Day 37
|
|
|
Tmax of VH4011499 when co-administered with Carbamazepine
Lasso di tempo: Day 41
|
Day 41
|
|
|
Apparent oral clearance (CL/F) of VH4011499 when administered alone
Lasso di tempo: Day 1 for Cohorts 1, 2 and 3
|
Day 1 for Cohorts 1, 2 and 3
|
|
|
CL/F of VH4011499 when co-administered with Ritonavir
Lasso di tempo: Day 26
|
Day 26
|
|
|
CL/F of VH4011499 when co-administered with Efavirenz
Lasso di tempo: Day 37
|
Day 37
|
|
|
CL/F of VH4011499 when co-administered with Carbamazepine
Lasso di tempo: Day 41
|
Day 41
|
|
|
Apparent terminal half-life (t1/2) of VH4011499 when administered alone
Lasso di tempo: Day 1 for Cohorts 1, 2 and 3
|
Day 1 for Cohorts 1, 2 and 3
|
|
|
t1/2 of VH4011499 when co-administered with Ritonavir
Lasso di tempo: Day 26
|
Day 26
|
|
|
t1/2 of VH4011499 when co-administered with Efavirenz
Lasso di tempo: Day 37
|
Day 37
|
|
|
t1/2 of VH4011499 when co-administered with Carbamazepine
Lasso di tempo: Day 41
|
Day 41
|
|
|
Cmax of VH4011499 when co-administered with Metformin and Digoxin
Lasso di tempo: Day 16
|
Day 16
|
|
|
AUC(0-t) of VH4011499 when co-administered with Metformin and Digoxin
Lasso di tempo: Day 16
|
Day 16
|
|
|
AUC(0-inf) of VH4011499 when co-administered with Metformin and Digoxin
Lasso di tempo: Day 16
|
Day 16
|
|
|
Cmax of Ritonavir when co-administered with VH4011499
Lasso di tempo: Day 26
|
Day 26
|
|
|
AUC(0-t) of Ritonavir when co-administered with VH4011499
Lasso di tempo: Day 26
|
Day 26
|
|
|
AUC(0-inf) of Ritonavir when co-administered with VH4011499
Lasso di tempo: Day 26
|
Day 26
|
|
|
Cmax of Efavirenz when co-administered with VH4011499
Lasso di tempo: Day 37
|
Day 37
|
|
|
AUC(0-t) of Efavirenz when co-administered with VH4011499
Lasso di tempo: Day 37
|
Day 37
|
|
|
AUC(0-inf) of Efavirenz when co-administered with VH4011499
Lasso di tempo: Day 37
|
Day 37
|
|
|
Cmax of Carbamazepine when co-administered with VH4011499
Lasso di tempo: Day 41
|
Day 41
|
|
|
AUC(0-t) of Carbamazepine when co-administered with VH4011499
Lasso di tempo: Day 41
|
Day 41
|
|
|
AUC(0-inf) of Carbamazepine when co-administered with VH4011499
Lasso di tempo: Day 41
|
Day 41
|
|
|
Cmax of VH4011499 when co-administered with Rosuvastatin
Lasso di tempo: Day 22
|
Day 22
|
|
|
AUC(0-t) of VH4011499 when co-administered with Rosuvastatin
Lasso di tempo: Day 22
|
Day 22
|
|
|
AUC(0-inf) of VH4011499 when co-administered with Rosuvastatin
Lasso di tempo: Day 22
|
Day 22
|
|
|
Cmax of VH4011499 when co-administered with Pitavastatin
Lasso di tempo: Day 17
|
Day 17
|
|
|
AUC(0-t) of VH4011499 when co-administered with Pitavastatin
Lasso di tempo: Day 17
|
Day 17
|
|
|
AUC(0-inf) of VH4011499 when co-administered with Pitavastatin
Lasso di tempo: Day 17
|
Day 17
|
Collaboratori e investigatori
Sponsor
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Infezioni a trasmissione ematica
- Malattie urogenitali
- Malattie genitali
- Malattie del sistema immunitario
- Infezioni
- Infezioni da virus a RNA
- Malattie virali
- Malattie trasmissibili
- Malattie sessualmente trasmissibili, virali
- Malattie trasmesse sessualmente
- Infezioni da lentivirus
- Infezioni da retroviridae
- Sindromi da deficit immunologico
- Malattie da virus lenti
- Infezioni da HIV
- Sindrome da immunodeficienza acquisita
- Composti di zolfo
- Prodotti chimici organici
- Composti eterociclici, 1-anello
- Composti eterociclici
- Composti eterociclici, anello fuso
- Tiazoli
- Azoli
- Idrocarburi
- Carboidrati
- Composti policiclici
- Glicosidi
- Amides
- Pirimidine
- Steroidi
- Composti anelli fusi
- Idrocarburi, alogenati
- Biguanides
- Guanidine
- Amidine
- Sulfonamidi
- Solfoni
- Dibenzazepine
- Composti eterociclici, 3 anelli
- Fluorobenzenes
- Idrocarburi, fluorurati
- Digitalis Glycosides
- Cardenolides
- Glicosidi cardiaci
- Cardanolidi
- Rosuvastatina Calcio
- Digossina
- Metformina
- Ritonavir
- Carbamazepina
- Efavirenz
- pitavastatina
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- 309014
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.viiv-studyregister.com/documents/About_ViiV_Patient_Level_Data_Sharing_Final_28May2026.pdf
Periodo di condivisione IPD
Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.
Criteri di accesso alla condivisione IPD
Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.
Tipo di informazioni di supporto alla condivisione IPD
- STUDIO_PROTOCOLLO
- LINFA
- ICF
- RSI
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .